S&P 500
738.20
+0.63%
DOW
521.46
+0.94%
NASDAQ
716.20
+0.36%
Russell
298.95
+1.23%
VIX
27.12
-3.14%
FTSE
45.48
-0.20%
Nikkei
92.92
+0.18%
BTC
60,250.00
-3.57%
ETH
1,618.22
-2.50%
Gold
367.13
-2.70%
Oil
106.94
-3.88%
Silver
53.09
-4.74%
S&P 500
738.20
+0.63%
DOW
521.46
+0.94%
NASDAQ
716.20
+0.36%
Russell
298.95
+1.23%
VIX
27.12
-3.14%
FTSE
45.48
-0.20%
Nikkei
92.92
+0.18%
BTC
60,250.00
-3.57%
ETH
1,618.22
-2.50%
Gold
367.13
-2.70%
Oil
106.94
-3.88%
Silver
53.09
-4.74%
Stock
Ti
News
Markets
Stocks
Screener
Calendar
Watchlist
Loading...
Home
/
Stocks
/
RGNX
/
News
RGNX
NASDAQ · Biotechnology
Regenxbio Inc
Small-Cap Stocks
Stocks Under $10
Biotech Stocks
Healthcare Stocks
$7.80
-0.10 (-1.27%)
☆ Watch
Overview
Earnings
Forecast
Financials
News
Peers
RGNX News
1 articles
REGENXBIO Shares Tumble 37% Despite Duchenne Gene Therapy Trial Success
REGENXBIO (RGNX) stock plummeted 37% to $6.31 despite positive Phase III data for RGX-202, as two serious adverse events and FDA approval doubts overshadowed the results.
Technology
May 14
↑